A new copper(II) complex-loaded Eudragit® nanoparticles against triple-negative breast cancer cells

Abstract

Platinum-based drugs are commonly used due to their effectiveness and ability to target various types of cancers. However, over time, cancer cells can develop drug resistance, making the treatment less effective. Additionally, these drugs can have high toxicity and cause harmful side effects in patients. On the other hand, copper-based complexes have attracted attention as potential alternatives. Early in vitro and in vivo studies have shown that they may have promising antitumor activities, offering a potentially effective and less toxic option for cancer treatment. Drug delivery systems offer significant benefits in cancer treatment by enhancing the delivery of therapeutics, reducing side effects, and improving drug efficacy and bioavailability at tumor sites. Eudragit polymers are widely used in drug delivery systems due to their versatility in controlling the release profile of drugs, offering protection to active compounds, and enhancing targeted delivery to specific areas of the body.